| Ytd | 25.03% | |
| 1y | 50.06% |
| Open | 34.66 | Prev Close | 34.45 | Low | 34.04 | High | 34.86 | Mkt Cap | 2.41B |
| Vol | 183.14K | Avg Vol | 436.96K | EPS | -3.19 | P/E | -10.81 | Forward P/E | -13.07 |
| Beta | -2.34 | Short Ratio | 2.39 | Inst. Own | 85.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 32.20 | 200-d Avg | 27.53 | 1yr Est | 47.27 |
PHVS News
ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?
Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rat
The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. Whil
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE att
ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmac
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of st
Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the business's
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a
Tudor Investment Corp ET AL purchased a new stake in Pharvaris N.V. (NASDAQ: PHVS) during the third
ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm
The mean of analysts' price targets for Pharvaris (PHVS) points to a 59.9% upside in the stock. Whil
ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm